Greg Abbott

Biography

Mr. Abbott has over 30 years of experience serving as Director, Chief Executive Officer and company officer of numerous biotech companies including Synergen and Darwin Molecular. He has also worked as a corporate and finance attorney and been a partner with the Silicon Valley law firm of Cooley LLP, for which he co-founded and managed a branch office in Kirkland, Washington. Previously, as a partner with Holme Roberts & Owen in Colorado, he led the firm’s technology practice and co-founded a branch office in Boulder, Colorado. Mr. Abbott has worked for many years as a biotech industry consultant, company advisor, and expert witness in biotech and technology licensing litigation. Today he is an Emeritus Attorney in the State of Washington, where he has volunteered on numerous cases for Northwest Immigrant Rights Project and served on its Board of Directors. He has also volunteered as an advisor to college-bound, low income, first generation students for College Access Now, and served on that organization’s Board of Directors. Mr. Abbott holds a B.A. from Yale, a J.D. with honors from the University of Denver Sturm College of Law, and has been a Fulbright Scholar in law in Moscow, Russia. 

Research Interest

AmideBio is a preclinical stage biotech company pursuing a series of therapeutic targets and diagnostic in the diabetes space. These include ultrastable insulin, glucose sensing insulin, solution stable glucagon and improved diagnostics for juvenile (T1) diabetes. In the diabetes space, a library of single chain insulin (SCI) analogs have been manufactured using a proprietary design protocol optimized for the production of SCI analogs that are resistant to thermal and chemical degradation at elevated temperature while maintaining maximal bioactivity